PHILADELPHIA, PA — Cabaletta Bio, Inc., a clinical-stage biotechnology company listed on NASDAQ (CABA), is set to make its mark at the 42nd Annual J.P. Morgan Healthcare Conference. The company announced that its Chief Executive Officer, Steven Nichtberger, M.D., will be presenting at the prestigious event on Tuesday, January 9, 2024.
The Pennsylvania-based company, known for its focus on the discovery and development of engineered T cell therapies, is expected to share insights about its work and future plans during the presentation. This could provide valuable information for investors and industry peers alike as they navigate the complex landscape of the healthcare sector.
The presentation is scheduled to start at 5:15 p.m. PT (8:15 p.m. ET) in San Francisco, California. For those unable to attend in person, the company has arranged a live webcast of the presentation. Interested parties can access this via the News and Events section of Cabaletta Bio’s website.
As one of the most highly anticipated events in the healthcare industry, the J.P. Morgan Healthcare Conference offers a platform for companies like Cabaletta Bio to showcase their contributions and future plans to a global audience. With the spotlight on them, all eyes will be on Nichtberger’s presentation to see what Cabaletta Bio has in store for the future.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.